La génomique dans l’ E space E uropéen de la R echerche Le 6ème programme cadre

1. La génomique • dans l’Espace Européen de la Recherche • Le 6ème programme cadre • Le contexte politique

3. LESS with MORE : less projects, higher focussing but more organisation implied FP5/QoL : mio € 2.2 FP6/TP1+TP5 : mio € 3.0 1800 Projects ~ 400 TI 20% ~ 200 NI 80%

4. 5th Framework Programme (1998 - 2002) The 6th Framework Programme (2002 - 2006) Quality of Life programme Thematic Priority 1 or 5 Bioethics Research Publicdialogue integration “wet” science Academia - Industry - Engineering “wet” science Ethics Innovation andcompetitiveness Innovation and technology transfer initiatives Socio-economic research Public dialogue Regulationand governance Fragmentation

5. Life Sciences, Genomics & biotechnology for health Life Sciences, Genomics and Biotechnology for Health (FP6) • Advanced Genomics and its applications for health (1100 M€) • Fundamental knowledge and basic tools for functional genomics • in all organisms • (Structural genomics; proteomics; comparative genomics; bioinformatics; • Multidisciplinary genomics approaches to basic biological processes) • Application of knowledge and technologies in the field of • genomics and biotechnology for health • (Technology platforms; support to start-up companies) • Combating major diseases (1155 M€) • Application-oriented approach to medical genomics knowledge • (Cardiovascular disease, diabetes and rare diseases ; resistance to • antibiotics ; Studying the brain and combating diseases of the nervous • system ; Studying human development and the ageing process) • Broader biomedical approach • (cancer, poverty-related infectious diseases)

9. Fundamental knowledge and basic tools for functional genomics in all organisms Structural genomics SECOND CALL TOPICS LSH-2003-1.1.2-1: Comparative structural biology of viral replication – IP.The focus should be on developing new approaches, tools and technologies for collecting comprehensive structural information on the replicative machinery of RNA viruses to facilitate the identification of potential new drug targets. LSH-2003-1.1.2-2: Structure determination of large protein complexes – IP. The focus should be on the high throughput isolation of cellular protein complexes under physiological conditions and their structural analysis.

10. Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes FIRST CALL TOPICS PROJECTS FUNDED The cell cycle Non-human embryonic stem cells Erythroid development and disorders Lymph/angiogenesis MITOCHECK (IP)Regulation of mitosis by phosphorylation FUNGENES (IP)Functional genomics in engineered mouse ES cells No project selected LYMPH/ANGIOGENOMICS (IP)Genome wide discovery and functional analysis of novel genes in lymph/angiogenesis

11. Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes FIRST CALL TOPICS PROJECTS FUNDED Epigenetics Chronic inflammation Ubiquitin-proteasome pathway THE EPIGENOME (NoE)Epigenetic plasticity of the genome +The European epigenetics network MAIN (NoE)Targeting cell migration in chronic inflammation No project selected

12. Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes SECOND CALL TOPICS LSH-2003-1.1.5-1: Functional genomics approaches in animal models to study human kidney disease – IP/NOE.The focus should be on integrating different expertise, animal models and functional genomics platforms to discover the genetic mechanisms that underlie kidney development and cause kidney disease. LSH-2003-1.1.5-2: Functional genomics approaches to the study of peroxisomes in health and disease – IP/NOE.The focus should be on using functional genomics approaches and cell and animal models to decipher the entire spectrum of biological functions performed by peroxisomes and to evaluate their roles in disease.

13. Fundamental knowledge and basic tools for functional genomics in all organisms Multidisciplinary functional genomics approaches to basic biological processes SECOND CALL TOPICS LSH-2003-1.1.5-5: DNA damage and repair mechanisms in health and disease – IP.The focusshould be on using multidisciplinary functional genomics approaches to decipher the core molecular mechanisms of DNA damage and repair. LSH-2003-1.1.5-6: Functional genomics approaches in animal models to study human immunological disease – IP/NOE.The focus should be on bringing together different expertise from academic and industrial (including SMEs) laboratories to generate a joint programme of activities that combines research on model organisms and functional genomics to investigate the immune system for elucidating the genetic basis of immunological disease, thereby facilitating the development of new diagnostics and therapeutic tools.

14. Fundamental knowledge and basic tools for functional genomics in all organisms STREPs and CAs FIRST CALL TOPICS SECOND CALL TOPICS Multidisciplinary functional genomics for basic mechanisms of: Transcription activation, signal transduction, intracellular communication, non coding genomic information, integration of genes, in silico predicion and simulation of regulatory networks Low abundance mRNAs and proteins, role of small RNAs, nanomachines, apoptosis, comparative genomics in protozoa, standardisation, in silico modelling of macromolecules. CA: Structuring mouse genomics and other models, systems biology, model organisms resources, biobanks 16 STREPs funded

15. Application of knowledge and technologies in the field of genomics and biotechnology for health Rational and accelerated development of new, safer and more effective drugs including pharmacogenomics approaches Development of new diagnostics Development of new in-vitro tests to replace animal experimentation Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies Innovative research in post-genomics, which has high potential for application

16. Application of knowledge and technologies in the field of genomics and biotechnology for health Diagnostics (2) Non-invasive advances in prenatal diagnosis (NoE) Molecular diagnostics of kidney disease Diagnostic for prion diseases (missing) New drugs (6) Protein-kinases - novel drug targets (IP) Drugs for depression (IP) Replication & integration of HIV (IP) Individualised medicines (missing) Blood substitutes G-protein coupled receptors European Labcourse: gene vectors (SSA) New Therapies (9) European consortium for stem cell research (IP) Allogeneic stem cell transplantation (IP) Mesenchymal stem cells for connective tissue disorders (IP) Genome & protein information for immune recognition Stem cells for myocardial repair Dendritic - cells / - Vaccines / - Cancer European Labcourse: therapy (SSA) In Vitro alternatives (3) Hazard and risk assessment of reproductive toxicity (IP) In vitro assays for long term toxicity Alternative methods (SSA) Post Genomics (6) New approaches for autoimmune diseases (IP) Pharmaceuticals from plants (IP) Antibiotic resistance - Gyrase inhibitors / - Glycopeptides Genomics - Biocatalysis Post-genomics drug discovery

17. Application of knowledge and technologies in the field of genomics and biotechnology for health • Post Genomics FIRST CALL: New approaches for autoimmune diseases (IP) Pharmaceuticals from plants (IP) Antibiotic resistance - Gyrase inhibitors / - Glycopeptides Genomics - Biocatalysis Post-genomics drug discovery SECOND CALL Exploitation of fungal genomics and filamentous fungal biotechnology for human health CA Induction of transplant tolerance IP Fungall cell-wall as a target of antifungal therapies STREP New bioassays and biosensors for detection of harmful microbes STREP RNA as a human therapeutic tool IP Use of RNAi as tool of post-genomic analysis SSA Novel biosafe propagation deficient virus vectors aimed at prevention and treatment of infectious diseases STREP Post-genomics approach to the study of human pathogens NoE

18. Total Food Chain Priority 5 Food Quality and Safety • Epidemiology of food related diseases and allergies • Impact of food on health • Traceability processes • Methods of analysis/detection and control of chemical • contaminants and pathogenic microorganisms • Safer production methods and healthier foodstuffs • Impact of Animal feed on Human Health • Environmental health risks

20. strategic objectives - nutrition science benefiting from new genomic technologies - virtual centre of excellence - transferring acquired knowledge to stakeholders’ groups

21. Figure 1. The three concentric activities of NuGO process of activities

22. integrating activities

23. joint research activities

24. Spreading of excellence Activities Training Dissemination Nutrigenomics and society Commercialisation The main NuGO Activities to Spread Excellence activities to spread excellence

25. Grain Legumes Integrated Project • New strategies to improve grain legumes for food and feed : • to increase competitiveness of grain legumes in Europe • to improve Europe’s self-sufficiency in plant proteins Grain legumes studied: pea, bean, faba bean, chickpea, lentil and lupin (the legume Medicago truncatula is used as a model system) 66 partners from 19 countries (~80 labs; 9 SMEs): UK; BE; BG; CH; CZ; DE; DK; ES; FR; HU; IL; IT; NL; NO; PL; PT; SE; AU; US Proposed budget: Total Costs: € 28.153.743 Requested EC Contribution € 16.961.701 (50% budget requested by 10 partners)

26. Grain Legumes Integrated Project Coordination & training Genetic & genomic tools Dissemination & transfer Bioinformatics TTP ~10 SMEs Seed composition & quality Crop functioning & seed quality Economic & environmental impact food, feed & health

27. “ERA-NET” Cooperation and coordination of national or regional research and innovation activities (i.e. programmes)

28. ERA-NET co-ordination action in plant genomics (ERA-PG) Participants: ERA-PG builds on national research programmes in plant genomics (NL, AT, BE, DK, FI FR, DE, IT, NO, SP, UK). Other states may join (BG, EE, GR, HU, IE, PO, PT, RO, SW) Objectives: • Improved co-ordination of national plant genomics research programmes • Optimising investments for plant genomics research and supporting policies • Creating long term perspectives and improved validation of RTD strategies Means: information exchange, web portal, short-term exchange of pgm managers, benchmarking, joint database of experts, position papers

30. 1. Harvesting the Potential The resource Base investing in people generating and exploiting knowledge intellectual property protection capital base Networking Europe’s Biotechnology Communities A pro-active role for public authorities 3. Responding to global challenge A European agenda for international collaboration Europe’s responsibilities towards the developing world 2. Governing Life Sciences and Biotechnology Societal scrutiny and dialogue Developing Life Sciences and Biotechnology in harmony with ethical values and social goals Demand-driven applications through informed choice Confidence in science-based regulatory oversight 4. Implementation and coherence across policies, sectors and actors A European Strategy for Life Sciences and Biotechnology: The Action Plan - COM (2002) 27

31. TECHNOLOGY PLATFORMS • European Council in March 2003 “ ...European Research and Innovation Area to be strengthened to the benefit of all in the enlarged EU by creating European technology platforms bringing together technological know-how, industry, regulators and financial institutions to develop a strategic agenda for leading technologies, in areas such as plant genomics …” • Technology Platforms have been identified as important elements for increasing competitiveness in the Communication “Industrial policy in an enlarged Europe” (Dec. 2002) and the “3% action plan” (April 2003)

32. 3% Action Plan: • better use of public financing to increase leverage effect on private investment; • R&D in corporate strategies and management. • Progress jointly (open process of co-ordination; European technology platforms) • Improve public support to research and innovation (human resources; academia-industry links; mix of public financing instruments; ..); • Redirect public spending towards research and innovation (refocus public spending; state aid rules; public procurement; ...)

34. Plant Genomics SHARED PLATFORM Industry Policy DGs Farmers cooperatives EPSO Biotech entrepreneurs Environmental NGO Consumer groups Policy-makers

35. LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH Improving the diagnostic and therapeutic arsenal for health care

36. TOWARDS JOINT INDUSTRIAL PROJECTS Treaty on the European Union Article 171 The Community may set up joint undertakings or any other structure necessary for the efficient execution of Community research, technological development and demonstration programmes E.g. GALILEO Joint Undertaking Members are EC, ESA, EIB, private enterprises. A tendering process is foreseen. Encompasses R&D, validation of developments, demonstration, coordination with national activities. Mio € 5.0 to be subscribed by entrerprises, down to € 250 000 for SMEs

37. European Research Council FP7 ? Joint Industrial Projects